Navigation Links
Martek Announces Fourth Quarter and FY 2007 Financial Results
Date:12/12/2007

very that contributed approximately 1% to gross margin. If not for this non-recurring item, gross profit margin in the fourth quarter would have been approximately 39%. Gross margin for the first quarter of fiscal 2008 is expected to be between 39% and 39.5%.

Research and development expenses in fiscal 2007 were $26.1 million compared to $24.8 million in fiscal 2006, an increase of 5.1%. R&D expenses in the fourth quarter of fiscal 2007 of $6.9 million were essentially unchanged as compared to the fourth quarter of fiscal 2006. The Company's research and development efforts continue to focus on developing new food and beverage applications for life'sDHA(TM), broadening the scientific evidence supporting the benefits of life'sDHA(TM) throughout life, improving manufacturing processes and developing new products to expand the Company's market offerings.

During fiscal 2007, selling, general and administrative expenses increased by $8.6 million, or 20.6%, from $41.6 million in fiscal 2006 to $50.2 million. This increase resulted primarily from additional resources invested in the Company's sales and marketing initiatives designed to grow its sales to infant formula customers overseas and to grow DHA markets outside of infant formula. More specifically, increased expenditures were made to expand the Company's sales, customer support and marketing personnel as well as to broaden the scope of the Company's advertising and public relations campaigns. The increase in SG&A costs over 2006 also included approximately $3.0 million of costs related to the Company's patent portfolio. Martek's intellectual property, and protection thereof, is critical to the Company's commercial success, and as such, the Company continues to invest resources in acquiring, maintaining and defending its intellectual property. The $700,000 sequential increase of SG&A costs over the third quarter of fiscal 2007 also relates primarily to higher patent-related costs.

Liquidity

<
'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The report “Smart Highway Market by ... Monitoring), and by Display (Variable Message Signs, Digital ... global market into various sub-segments with in-depth analysis ... drivers and restraints for this market with insights ... market tables and 37 figures spread through 141 ...
(Date:10/27/2014)... -- Investor-Edge has initiated coverage on the ... ), Insmed Inc. (NASDAQ: INSM ), BioCryst ... (NASDAQ: DYAX ), and Oncothyreon Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . On Friday, ... up 0.69%, the Dow Jones Industrial Average advanced 0.76%, ...
(Date:10/25/2014)... The report “Adipic Acid Market by ... Global Trends & Forecast to 2019” report analyzes ... drivers, opportunities, and trends in different regions. , ... spread through 217 slides and in-depth TOC on ... to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will ...
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... NEW YORK, March 9, 2011 Reportlinker.com announces ... in its catalogue: World Market ... and What,s Not, The ... predictions made about the molecular diagnostics but to ...
... 2011 SPX Corporation (NYSE: SPW ) ... B.W. Murdoch Ltd, a leading engineering company supplying processing ... is based in Auckland, New Zealand. Terms of the ... has decades of experience in the New Zealand dairy, ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
Cached Biology Technology:Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 2Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 3SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... all the genetic sequences in living organisms, has leaned ... the blueprint, unfortunately, has been unintelligible, with no good ... link genomic features to cell function. , A national ... non-profit research center, and Pacific Northwest National Laboratory (PNNL), ...
... Medicine have identified a link between a critical cancer ... be expressed in a number of EBV-associated cancers. Their ... human B cells from the immune system into cancerous ... , Erle S. Robertson, PhD, Associate Professor of Microbiology ...
... target in their fight against a dangerous bacterium that ... implants such as catheters, artificial joints and heart valves. ... epidermidis has, for the first time, been shown to ... that would otherwise kill the bacteria, according to scientists ...
Cached Biology News:Fleshing out the genome 2Defensins neutralize anthrax toxin 2Substance protects resilient staph bacteria 2
...
... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... pAcAB4 vector is a 10.0 kb Autographa ... two,copies of the AcNPV polyhedrin promoter and ... first p10,promoter is a Sma I cloning ... Upstream of this,an inverted polyhedrin promoter has ...
Biology Products: